Herantis Pharma
2.59 EUR
+7.47 %
4,492 following
HRTIS
First North Finland
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Investor consensus
+7.47 %
+26.96 %
+21.60 %
-4.78 %
+70.39 %
+57.93 %
+16.67 %
-34.06 %
-74.28 %
Herantis Pharma Plc is a clinical-stage biotechnology company developing disease modifying therapies for Parkinson’s disease. Herantis’ lead product HER-096 is a small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein. HER-096 combines the mechanism of action of CDNF with subcutaneous administration. The Phase 1a clinical trial demonstrated a good safety and tolerability profile as well as blood-brain barrier penetration of subcutaneously administered HER-096. The shares of Herantis are listed on the Nasdaq First North Growth Market Finland.
Read moreMarket cap
62.41M EUR
Turnover
1.12M EUR
P/E (adj.) (25e)
-10.38
EV/EBIT (adj.) (25e)
-11.6
P/B (25e)
-47.82
EV/S (25e)
6,396.09
Dividend yield-% (25e)
-
Coverage
Analyst
Revenue and EBIT-%
Revenue K
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
5/3
2026
Annual report '25
23/4
2026
General meeting '26
20/8
2026
Interim report Q2'26
Risk
Business risk
Valuation risk
Low
High
All
Research
Webcasts
Press releases
3rd party
ShowingAll content types
Herantis' latest analysis reveals HER-096's activity in central nervous system
Herantis Pharma - Phase 1b biomarker data show clear evidence of biological response to HER-096 in people with Parkinson's disease
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
